一种由九个血小板相关基因特征组成的新型风险模型，用于预测胶质瘤的预后、免疫特征和药物敏感性。
A novel risk model consisting of nine platelet-related gene signatures for predicting prognosis, immune features and drug sensitivity in glioma.
作者信息
Wei Sanlin, Zhou Junke, Dong Bin
机构信息
Dalian Medical University, Dalian, Liaoning Province, 116000, China.
Department of Neurosurgery, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, 116000, China.
出版信息
Hereditas. 2024 Dec 20;161(1):52. doi: 10.1186/s41065-024-00355-7.
BACKGROUND
Glioma is a malignancy with challenging clinical treatment and poor prognosis. Platelets are closely associated with tumor growth, propagation, invasion, and angiogenesis. However, the role of platelet-related genes in glioma treatment and prognosis remains unclear.
RESULTS
A prognostic risk model was established using nine platelet-related prognostic signature genes (CAPG, CLIC1, GLB1, GNG12, KIF20A, PDIA4, SULF2, TAGLN2, and WEE1), and the risk score of samples were calculated. Subsequently, the glioma samples were divided into high- and low-risk groups based on the median values of risk scores. scRNA-seq analysis revealed that the prognostic genes were primarily located in astrocytes and natural killer cells. The immune infiltration proportions of most immune cells differed significantly between high- and low-risk groups. Moreover, we found AZD7762 as a potential candidate for glioma treatment.
CONCLUSION
Nine platelet-related prognostic genes identified as prognostic signatures for glioma were closely associated with the TME and may aid in directing the clinical treatment and prognosis of gliomas.
背景
胶质瘤是一种临床治疗具有挑战性且预后较差的恶性肿瘤。血小板与肿瘤生长、增殖、侵袭和血管生成密切相关。然而，血小板相关基因在胶质瘤治疗和预后中的作用仍不清楚。
结果
利用9个血小板相关预后特征基因（CAPG、CLIC1、GLB1、GNG12、KIF20A、PDIA4、SULF2、TAGLN2和WEE1）建立了预后风险模型，并计算了样本的风险评分。随后，根据风险评分的中位数将胶质瘤样本分为高风险组和低风险组。单细胞RNA测序分析显示，预后基因主要位于星形胶质细胞和自然杀伤细胞中。高风险组和低风险组中大多数免疫细胞的免疫浸润比例存在显著差异。此外，我们发现AZD7762是胶质瘤治疗的潜在候选药物。
结论
鉴定出的9个血小板相关预后基因作为胶质瘤的预后特征，与肿瘤微环境密切相关，可能有助于指导胶质瘤的临床治疗和预后评估。
Zotero 插件